
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early stage ADCs pursuing undisclosed solid tumor targets.
The HCP Non-Personal & Omnichannel Marketing Lead will lead the development of an integrated non-personal promotion, media, and omnichannel plan in support of the U.S. launch of Varegacestat. This role will play a critical part in building and optimizing a seamless, data-driven HCP experience across digital and non-personal channels to drive disease awareness, education, and brand adoption. In addition, this role will champion innovation by identifying and implementing emerging digital capabilities, including the responsible use of AI, to enhance HCP engagement, personalization, content development, and marketing effectiveness. The role requires a strategic thinker with strong digital marketing expertise, launch experience, and a deep understanding of HCP engagement in the oncology marketplace.
Responsibilities
Digital Marketing & Non-Personal Promotion
Omnichannel Strategy & Execution
Innovation & AI Enablement
Qualifications
Knowledge and Skills
Washington State Pay Range $190,000—$230,000 USD
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish)

Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.